Amgen Quarterly Report: Profits Up, HCR Fears Down
This article was originally published in The Pink Sheet Daily
Executive Summary
Amgen says health care reform will trim its sails, but it's not much compared to the blow it took from the ESA safety problems.
You may also be interested in...
Health Care Reform's Impact Reflected In Pharma's Q1 Results
President Obama had barely put his signature to the new health care reform law when its impact on biopharma became clear. With Lilly in the lead, a parade of companies posted first quarter financial results which underscored a key point for the industry: it is bearing costs of the new law immediately, but won't reap the benefits for several years
Health Care Reform's Impact Reflected In Pharma's Q1 Results
President Obama had barely put his signature to the new health care reform law when its impact on biopharma became clear. With Lilly in the lead, a parade of companies posted first quarter financial results which underscored a key point for the industry: it is bearing costs of the new law immediately, but won't reap the benefits for several years
Amgen Highlights Effects Of Health Reform Provisions In Earnings Call
While Amgen's bottom line will take a hit in the wake of the new health care reform law, the impact is expected to minimal enough that officials did not have to change previously reported guidance